News Release

Future Science Group launches new initiative, PharmaPlatforms

Future Science Group is delighted to announce the launch of a new arm of its business, PharmaPlatforms

Business Announcement

Future Science Group

Recognising the need for cohesive and collaborative communication plans around published content, Future Science Group (FSG; London, UK) is delighted to announce the launch of a new arm of its business, PharmaPlatforms. Taking published content from FSG's journals, knowledge networks and content hubs, PharmaPlatforms will provide a range of solutions that enrich the information presented, engage the reader, and reach a broad scientific and medical professional audience.

"Publishing has progressed rapidly in the past 5-10 years, not only in terms of technology but the sheer volume of scientific articles that are published each year. Time-constrained healthcare practitioners are inundated with scientific literature daily leaving little, if any, time to read even the most important research in their field," explains Joanne Walker, Managing Director, PharmaPlatforms. "Our vision is to build on published content, leveraging our in-house editorial, graphical and digital expertise to present information in an engaging format that is easily digested and discoverable by the right audience."

"Having worked with medical publication professionals over a number of years," continues Joanne, "I am really excited to provide this community with new innovative options to enhance the content they produce, which will be to the benefit of all involved, including authors, readers, and ultimately the patient."

To find out more about PharmaPlatforms, please visit http://www.pharmaplatforms.com

###

About Future Science Group

Founded in 2001, FSG is a progressive publisher focused on breakthrough medical, biotechnological and scientific research. FSG's portfolio consists of three imprints, Future Medicine, Future Science and Newlands Press, publishing both eBooks and journals. In addition to this core publishing business, FSG develops specialist knowledge networks and content hubs, enabling professionals to easily connect and collaborate with their peers in niche scientific fields.

FSG currently publishes 34 peer-reviewed journals as well as 8 knowledge networks and content hubs across a wide range of therapy area and scientific fields. Key journals include Future Microbiology, Future Oncology and the Journal of Comparative Effectiveness Research, alongside sites such as Infectious Diseases Hub, Oncology Central and The Evidence Base.

The aim of FSG is to service the advancement of clinical practice and drug research by enhancing the efficiency of communications among clinicians, researchers and decision-makers, and by providing innovative solutions to their information needs. This is achieved through a customer-centric approach, use of new technologies, products that deliver value-for-money and uncompromisingly high standards.


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.